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E-mail: 15268jta@comb.catSystemic lupus erythematosus is a highly complex and hetero-
geneous autoimmune disease mostly mediated by B cells. It is
characterized by circulating self-reactive antibodies that depo-
sit and form immune complexes in kidney, leading to irrepa-
rable tissue damage and resulting in lupus nephritis. In a
New Zealand Black X New Zealand White F1 mouse model,
we tested two different small interfering RNA (siRNA)
silencing treatments against interferon regulatory factor 5
(IRF5) and B cell-activating factor (BLYSS) expression and
their combination in a second set of animals. The administra-
tion of these two siRNAs separately prevented the progression
of proteinuria and albuminuria at similar levels to that in cyclo-
phosphamide animals. These treatments effectively resulted in
a reduction of serum anti-double-stranded DNA (dsDNA) an-
tibodies and histopathological renal score compared with non-
treated group. Treated groups showed macrophage, T cell, and
B cell infiltrate reduction in renal tissue.Moreover, kidney gene
expression analysis revealed that siRNA treatments modulated
very few pathways in contrast to cyclophosphamide, despite
showing similar therapeutic effects. Additionally, the com-
bined therapy tested in a second set of animals, in which the
disease appeared more virulent, exhibited better results than
monotherapies in the disease progression, delaying the disease
onset and ameliorating the disease outcome. Herein, we pro-
vide the potential therapeutic effect of both selective IRF5
and BLYSS silencing as an effective and potential treatment,
particularly in early phases of the disease.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a complex, heterogeneous, and
chronic autoimmune disorder. SLE is a B cell-mediated autoimmune
disease in which autoantibodies, such as anti-double-stranded DNA
(dsDNA) autoantibodies, form immune complexes that are deposited
in different tissues, resulting in multiple inflammatory lesions and tis-Molecular T
This is an open access article under the CC BY-NC-sue damage.1–3 One of the most serious related complications is lupus
nephritis (LN), which can lead to severe proteinuria, chronic renal
failure, and end-stage kidney disease. This complication remains
the leading cause of short-term morbidity and mortality.4 The stan-
dard treatment for SLE is immunosuppression with corticosteroids
and cyclophosphamide (CYP) and more recently with mycopheno-
late (Mofetil). However, these long-term treatments produce non-
negligible adverse effects. Therefore, it is desirable to improve disease
outcomes and quality of life by introducing new treatments with
fewer side effects.1,2,5
A feature of the immune system activation in SLE is the presence of
increased circulating interferon (IFN)-a, which correlates with dis-
ease activity.6 Most patients with SLE show evidence of type I IFN in-
crease, but frequently with dysregulated expression of genes in the
IFN pathway. Furthermore, this IFN gene expression “signature”
served as a marker for more severe diseases involving the kidneys.7
IFN production occurs when Toll-like receptors (TLRs) detect certain
pathogen-associated molecular patterns (PAMPs); TLRs initiate
signaling by inducing phosphorylation of the IFN regulatory factors
(IRFs) type 3, 5, and 7 that, in turn, induce transcription of IFN-
related genes.8 Once produced, type I IFNs exert an activating effect
on dendritic cells (DCs), triggering higher expression of costimula-
tory molecules, major histocompatibility complex class I (MHC class
I)/II proteins, chemokines, and chemokine receptors.9 IFN alsoherapy: Nucleic Acids Vol. 24 June 2021 ª 2021 The Authors. 807
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1. Sequence description and target localization of the siRNAs



















































Molecular Therapy: Nucleic Acidsstimulates the activation of T and B cells, leading to antibody
production.10
IRF5 genetic variants and disease-associated factors contribute to
enhanced IRF5 expression in blood cells of SLE patients, with the
risk of disease progression.11–14 IRF5 is necessary for the development
of a lupus-like disease in both New Zealand Black X New Zealand
White F1 (NZB/WF1) and MRL/lpr mice,15,16 and the permanent ef-
fect of IFN can be instrumental in perpetuation of the autoimmune
process.16,17 Results from clinical studies in patients with SLE with
anti-IFN-a monoclonal antibodies suggest that reduced expression
of IFN-inducible genes could lead to a decrease in pro-inflammatory
activity and clinical improvement.18–20
B cell-activating factor (BLYSS) is a transmembrane glycoprotein in
the tumor necrosis factor (TNF) ligand superfamily that is involved
particularly in B cell maturation.21–23 Autoreactive B cell clones
require higher levels of BLYSS for their survival. BLYSS overexpres-808 Molecular Therapy: Nucleic Acids Vol. 24 June 2021sion causes SLE, and its inhibition can delay the disease in murine
models. Therefore, BLYSS inhibition has recently become a prom-
ising therapeutic target for SLE.24–27 BLYSS expression is induced
in vivo by type I IFN, but the exact molecular mechanisms and its
relation to IRF5 remain unknown.28 Comprehending how the expres-
sion of BLYSS is related to type I IFN system activation in SLE might
provide important clues to understanding the mechanisms of the dis-
ease. BLYSS expression is directly downstream to the type I IFN
signaling, and the members of the IRF family tightly regulate the
expression of BLYSS. Thus, there is a critical interrelation between
both networks. This leads to the hypothesis that in vivo blockade of
both pathways concurrently could multiply their protective effects
in LN.
RNA interference is a posttranscriptional genetic phenomenon inhib-
iting gene expression, and it is mediated by double-stranded RNA.
Small interfering RNAs (siRNAs) act as leader sequences, joining
nuclease activity protein complexes (RNA-induced silencing complex
[RISC]), and the positioning in the mRNA target allows the specific
target degradation. The main advantages of siRNAs are their high ef-
ficiency, potency, and specificity, thereby allowing their use at low
concentrations with a highly specific gene expression inhibition. In
addition, some chemical modifications result in siRNA molecules
becoming resistant to degradation by nucleases and improving their
distribution, half-life, and cellular uptake.29–31 Despite recent ad-
vances in delivering siRNA, the immunogenicity of siRNA and the
delivery vehicle (Veh) remain challenging, especially when repeated
dosing is needed to treat chronic or degenerative diseases. We used
a murine-specific siRNA, chemically stabilized and cholesterol conju-
gated, in a model of autoimmune nephritis where we demonstrate
that systemic blockade induced immune deactivation of the injured
kidneys.1
In the current study, the BLYSS and IRF5 blockade effects with our spe-
cifically designed siRNAs were analyzed in NZB/WF1mice with estab-
lished autoimmune nephritis. We hypothesized that blocking IRF5
expression would reduce the IFN-cascade-mediated signals and that
the BLYSS blockade would reduce the secretion of antibodies and for-
mation of immune complexes. Moreover, we developed the study
with a multi-target strategy with these two functional and tested mole-
cules, hypothesizing their additive effect.32,33 We analyzed the disease
evolution and the modulation of renal histological lesions, mainly in
the glomerular compartment, and tried to providemechanistic insights
focusingon renal gene signature. Furthermore,we assessedwhether sys-
temic siRNA administrations affected spleen cell populations.
RESULTS
Anti-mouse IRF5 and BLYSS siRNA selection
Fourteen and 12 siRNAs were designed to target different positions
within the coding region of mouse IRF5 (Table 1) and BLYSS (Table
2) mRNA, respectively (see Materials and methods for procedures).
Twenty-four hours after transfection into cells, IRF5 and BLYSS RNA
expression was measured relative to 18s rRNA levels
using quantitative real-time PCR and then normalized to the mRNA
Table 2. Sequence description and target localization of the siRNAs designed to screen for efficient mouse BLYSS mRNA silencing





































www.moleculartherapy.orglevels of the non-targeting control (Figures 1 and 2). Several of these
siRNAs had significant knockdown efficacy. However, taking into ac-
count the replicates and the different doses that were tested in RAW
264.7 cell culture, siRNA-3 was finally chosen for IRF5 silencing (re-
named as siIRF5); and in MCP11 cell culture, siRNA-4 was selected
for BLYSS silencing (renamed as siBLYSS) for the subsequent in vivo
study.
First set of experiments with siRNA monotherapy transfection
After siRNA selection, animals received either siIRF5 or siBLYSS in
monotherapy and fully adhered to the established protocol. Different
disease outcomes and cumulative survival were observed, depending
on the treatments, as presented in Figures 3 and 4 and Table 3.
Effect of siRNA monotherapy transfection in LN model
Proteinuria levels increased progressively in Veh and scrambled non-
silencing siRNA (SC) groups (Figure 3). By contrast, monotherapy-
treated groups showed a significant diminution of proteinuria
compared with Veh and SC groups at the end. Albuminuria levels fol-
lowed a similar pattern as proteinuria. IRF5 and BLYSS groups had
significantly lower proteinuria and albuminuria levels than the control
groups.
According to histopathological evaluation, untreated animals devel-
oped typical and severe lesions of LN (Figure 4). siIRF5 treatment
produced a global reduction in the evaluated lesions. Regarding si-BLYSS treatment, the almost complete disappearance of glomerular
deposits and a reduction in interstitial infiltrates, tubular atrophy,
and interstitial fibrosis were prominent. BLYSS and intraperitoneal
CYP groups displayed significantly less structural damage compared
with the SC and Veh groups.
Levels of renal infiltrating CD3+ cells (T cell) were reduced in treated
groups compared with the SC group, demonstrating their therapeutic
effect. A reduction of CD45RA+ (B cell) infiltrate was only observed in
siBLYSS treatment.
Anti-dsDNA antibody progression was also lower in treated groups.
The significantly lowest increase was observed in the CYP group. The
reduction of this circulating immunological marker of the disease
paralleled the significant reduction of both renal immunoglobulin
G (IgG) and complement 3 (C3) in all treated groups.Analysis of peripheral blood, spleen, and kidney cell populations
with flow cytometry
Peripheral blood analysis displayed different cell population changes,
depending on the treatments. Animals treated with siIRF5 revealed a
decrease in B cell population. Despite the reduction of CD4+ T cells,
an increase in the CD3+ T cell population was observed, mainly due to
the regulatory T cells (Tregs) expansion. The siIRF5 treatment also
induced an increase of regenerating monocytes.Molecular Therapy: Nucleic Acids Vol. 24 June 2021 809
Figure 1. Knockdown efficiency of siRNA in vitro transfection (10, 15, and 50 nM) sequences against mouse IRF5
The synthesized siRNAs were assayed in RAW 264.7 cell line (macrophages). The amount of IRF5 mRNAwasmeasured relative to 18s rRNA levels using qRT-PCR and then
normalized to the mRNA levels of the non-targeting control, 24 h post-transfection. Results are given as mean ± SEM from two independent experiments performed in
duplicate.
Figure 2. Knockdown efficiency of siRNA in vitro transfection (10, 15, and 50 nM) sequences against mouse BLYSS
The synthesized siRNAs were assayed in MCP11 cell line (B lymphocytes). The amount of BLYSSmRNA was measured relative to 18s rRNA levels using qRT-PCR and then
normalized to the mRNA levels of the non-targeting control, 24 h post-transfection. Results are given as mean ± SEM from two independent experiments performed in
duplicate.
Molecular Therapy: Nucleic AcidsBLYSS silencing also showed a B cell reduction alongside a CD3+
T cell increase; but in this case, the double-positive CD4+CD8+
T cells were the most expanded subpopulation. This treatment also
increased the precursor DC (pDC) population.
Finally, animals treated with CYP revealed an increase of regulatory B
cells (B-regs), regenerating monocytes, and pDC subpopulations. A
reduction of CD4+ T cells was also observed; however, there was an
increase in the total amount of CD3+ T cells.
Concerning spleen analysis, all treated groups showed an increase in
B-reg and B1 cell populations.810 Molecular Therapy: Nucleic Acids Vol. 24 June 2021By contrast, a reduction was seen regarding B2 cells, DC popula-
tions, and M1 macrophages. M2 macrophages were increased
only in siBLYSS- and CYP-treated animals. With regard to
CD3+ T cell population, only slight changes were noticed between
groups.
Kidney tissue analysis showed a significant decrease in infiltrating B
cells and macrophages in all treated groups. A reduction of CD3+
T cell and DC infiltrate was also revealed. IRF5-silencing group also
exhibited an increase in B-reg recruitment.
The complete cytometry data are provided in the Supplemental
information.
Figure 3. Functional renal parameters for the first set of experiments throughout the study for all treatments
(A and B) Functional renal parameters for the first set of experiments including (A) proteinuria and (B) albuminuria by weight. Values are expressed inmg/kg for 24 h. (C) Serum
anti-dsDNA levels throughout the study for all treatments are expressed in kilo units/mL. Data are expressed as mean. a, p < 0.05 versus Veh; b, p < 0.05 versus SC.
www.moleculartherapy.orgSerum T helper 1 (Th1) and Th2 inflammatory cytokines
Levels of serum TNF, MCP1, interleukin-10 (IL-10), IL-6, and INF-g
were quantified in all surviving animals at the end of the study (Fig-
ure 5). Significant reductions of TNF levels in CYP and IRF5 groups
and amoderate reduction in BLYSS group comparedwith the SC group
were detected. MCP1 and IL-10 values were significantly decreased in
all treated groups. IL-6 levels were also significantly reduced in IRF5
group and clearly, but not significantly, diminished in CYP and BLYSS
groups. Finally, IRF5 was the group with the lowest IFN-g levels.
Gene expression analysis profile
An array of 384 genes involved in LN was configured. Following the
development of the array, 23 genes were discarded for technical rea-
sons and 361 genes were finally included. The results showed that 284
genes were significantly modulated by CYP: 32 by siBLYSS and only
18 by siIRF5. Curiously, only the Tnfsf13 gene was significantly modi-
fied (downregulated in this case) by the two siRNA treatments.
PathwAX results indicated that siIRF5 affected fourteen molecular
pathways related to immune diseases such as diabetes and inflamma-
tion. It also affected six metabolism-related pathways, oxidation, and
phosphorylation processes as the most significant. Of note is that it
affected five pathways related to the processing of genetic information,
activating genes related to the proteasome and inhibiting some genesrelated to the synthesis, transport, and modification of RNA, and one
single pathway related to cellular senescence process. siBLYSS modu-
lated pathways related to metabolism and cellular adhesion and mod-
ulation pathways such as mitogen-activated protein (MAP) kinases, Ja-
nus kinase-signal transducer and activator of transcription (JAK-
STAT), TNF, and cyclic MAP (cAMP). All the pathways related to ge-
netic information processing are depleted with respect to modulated
pathological pathways, which suggests that the groups have fewer con-
nections in the real network than expected from the random model,
indicating that they have crosstalk depletion. In this case, the associa-
tion with SLE appears with a q value of 8,312e9, which includes 27
of the 32 significantly modulated genes analyzed in the array: DlD,
Sod2, and Pdha1 are the genes with the most related pathways.
All of these results demonstrate that CYP treatment is strikingly
active at the molecular level, but the designed siBLYSS and siIRF5
treatments cause a significant reduction in the disease evolution
through the modulation of few targets. The list of all analyzed genes
is provided in Supplemental information.
Second set of experiments with siRNA monotherapy and
combined transfection
A second set of experiments was undertaken to confirm the efficacy
of the gene-silencing approach and to assess a potential synergistic orMolecular Therapy: Nucleic Acids Vol. 24 June 2021 811
(legend on next page)
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Table 3. Survival differences between the two sets of experiments
Initial n Final n Survival (%)
1st set
Vehicle 8 8 100
SC 7 7 100
IRF5 8 8 100
BLYSS 8 6 75
CYP 8 8 100
2nd set
Vehicle 8 6 75
SC 7 6 85.7
IRF5 8 7 87.5
BLYSS 8 8 100
DUAL 10 10 100
CYP 8 8 100
www.moleculartherapy.orgadditive effect with the combined treatment. The cumulative survival in
untreated groups was lower than that of the first set of experiments,
which reveals greater disease virulence in this litter of animals (Table 3).
Validation of siRNA silencing in vivo
Expression of circulating IRF5 was significantly lower in the siIRF5
and intraperitoneal BLYSS-siRNA+IRF5-siRNA (DUAL) groups
than in the untreated groups, as expected. Similar results occurred
with circulating BLYSS. The treatments that significantly reduced
these levels were in siBLYSS, CYP, and DUAL groups. Additionally,
IFN-a was significantly reduced in siRF5 and DUAL groups with
respect to the SC group (Figure 6).
Effect of dual siRNA therapy in LN model
As seen in Figure 7, when compared with all treated groups, SC and
Veh groups displayed a worse level of proteinuria. siRNA monother-
apy provided a less aggressive worsening slope, while DUAL group
offered clearly and significantly better proteinuria, quite similar to
that of the CYP group, with steady low values throughout the study.
Albuminuria levels were largely higher than the first SLE set, again
indicating a greater virulence of the disease, but it followed the
same profile as proteinuria. Additionally, levels of anti-dsDNA anti-
bodies were higher in this second study. The progressive increase in
Veh group was significantly higher than that in all treated groups.
Proteinuria excretion over 3 mg/24 h during the study was considered
a negative disease outcome. In this regard, substantial differences be-Figure 4. Renal histopathology parameters for the first set of experiments
(A) Semiquantitative inflammatory score values for hematoxylin and eosin stain. (B) Dot
power field (HPF) values for renal immunofluorescence CD3+ infiltrate and semiquanti
glomerular C3 and IgG deposition were measured under a confocal microscope. Data
versus Veh; b, p < 0.05 versus SC.tween CYP and DUAL (only 12.5 and 20% proteinuria exceeding
3 mg/24 h, respectively) from the untreated groups (57.1% in SC
and 87.5% in Veh) were observed (Table 4). Thus, DUAL therapy
further provided better proteinuria outcome than monotherapy.
Anti-dsDNA antibodies were also higher than in the first set. They
progressively increased in Veh group and were significantly higher
than in all treated groups.
According to the histopathological evaluation (Figures 8 and 9), a
greater efficacy of siIRF5 was observed, without evidence of intersti-
tial fibrosis and less cell proliferation than with the siBLYSS treat-
ment. DUAL treatment showed lower histological score that was
significantly different from Veh and similar to CYP.
CD3+, CD45RA+, and F4/80+ quantification in the DUAL group was
lower than in siRNA monotherapy groups, although higher than in
the CYP group. Interestingly, DUAL therapy reduced glomerular B
cell to levels similar to CYP. Regarding F4/80+, siBLYSS reduced
the infiltration better than siIRF5, with both better than Veh group.
DUAL treatment showed significantly lower levels of T cells andmac-
rophages than Veh.
DISCUSSION
These two studies with a well-recognized model of autoimmune
nephritis have shown the reduction of the disease outcome and pro-
gression with both selective gene-silencing siRNA treatments. More-
over, the study with siRNA combination shows clearly better results
in animals treated with DUAL therapy compared with siRNA mono-
therapy, substantiating an additive effect of IRF5 and BLYSS.
In the first set of experiments, mice treated with siIRF5 or siBLYSS
displayed a better renal function than non-treated mice. These effects
were accompanied by a significant reduction of circulating anti-
dsDNA and renal histopathological lesions. Data also showed the
same trend regarding C3 and IgG renal deposits as well as renal
T cell infiltrate. These results validate the satisfactory LN protection
using a highly targeted gene silencing, similar to the protection
offered by CYP.
Interestingly, BLYSS silencing reduced the renal B cell infiltrate
compared with untreated animals, while the IRF5 silencing did not.
This phenomenonmay be due to the lower hierarchy of the IFN signal
in the B cell recruitment in this setting. IRF5 signal can be found
mechanistically prior to BLYSS,34,35 but these results suggest that
the BLYSS signal plays a more important role in the B cell recruitment
than does the IRF5 signal. This fact also demonstrates that the BLYSS
signal does not only depend on the previous IRF5 signal and the IFNplot representation of total inflammatory score for each animal. (C) Cells per high-
tative score for CD45RA+ infiltrate staining. Mean fluorescence intensity values for
are expressed as mean ± SEM with individual dot plot representation. a, p < 0.05
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Figure 5. Serum levels of TNF-a, INF-g, MCP1, IL-10, and IL-6 at the end of the first set of experiments for all treatments
Values are expressed in pg/mL. Data are expressed as mean ± SEM with individual dot plot representation. a, p < 0.05 versus Veh; b, p < 0.05 versus SC.
Molecular Therapy: Nucleic Acidsrelease to exert its function. In fact, these results showed that BLYSS
can act without the presence or in the presence of low levels of these
cytokines. However, the modulatory effect conferred by IRF5 treat-
ment represents an overall improvement, which gives credence to un-
dertaking the DUAL treatment with both siRNAs.
Cell recruitment reduction in renal parenchymawas a relevant finding
in this study, in accordance with the well-characterized excessive acti-
vation, signaling, and migration of both B/T cells in this disease.36,37814 Molecular Therapy: Nucleic Acids Vol. 24 June 2021Therefore, we lookedmore deeply into this cell dynamics by analyzing
B cell subsets among other inflammation and autoimmunity subsets in
renal tissue, spleen, and peripheral blood to assess the treatment differ-
ences. Renal cytometry confirmed the results in immunochemical B
cell infiltrate. Cytometry also allowed us to discern different B cell sub-
sets such asB1, B2, or B-regs. This approach elicited an expansion of B-
regs under the IRF5 silencing. This shows that the overall increase in B
cells observed in immunohistochemistry is due to the increase in B-
regs in IRF5 group. Hence, treatment with siIRF5 involved an increase
Figure 6. Endpoint serum circulating IRF5, BLYSS, and IFN-a levels for the
second set of experiments
Values are expressed in ng/mL. Data are expressed as mean ± SEM with individual
dot plot representation. a, p < 0.05 versus Veh; b, p < 0.05 versus SC.
www.moleculartherapy.orgin B-regs that favored the palliation of the disease. This therapeutic ef-
fect given by siIRF5 treatment is like the effect observed with CYP,
although it involves another pathway to alleviate the disease. In the
case of siBLYSS silencing, no significant movements were observed
in kidney-infiltrating B-regs. Regardless, an expected general reduc-
tion in kidney B cells was detected and attributable to the silencing
of this B cell activation factor. An increase in B-regs and B1 cells in
the spleen was also observed in both treated groups, as well as a reduc-tion in B2 cells. These changes were associated with reduced release of
anti-dsDNA antibodies, renal IgG, and C3 deposits, which is a partic-
ular occurrence inmouse and human LN.38–40 This phenomenonmay
be due to the immunomodulatory capacity of B1 cells as well as B-regs,
which suppress IFN and TNF from T cells and release various regula-
tory cytokines.41 By contrast, B2 cells have been described as cells with
a function contrary to those mentioned above.
In the case of T cells, solid changes similar to immunohistochemistry
were observed in the kidney in all treatments, where there was a
reduction of these T cells compared with SC group. This phenome-
non was observed in almost all other pro-inflammatory and im-
mune-response-related cells, such as DCs and macrophages in the
renal tissue and spleen. Macrophages were generally reduced in the
kidney, but the M2 spleen subset, which is a subpopulation of macro-
phages with immunosuppressive activity, was significantly increased
in CYP and BLYSS groups. Additionally, the inflammatory M1 subset
in the spleen was reduced in all treated groups. The blood-circulating
monocytes were also analyzed, and an increase of the Ly6C-regen-
erating subset was observed in IRF5 and CYP groups. There were
no essential differences in Treg population. Nevertheless, the largest
differences were observed in the B cells and their subsets; as seen in
other studies, this model should be more related to B cells and B-
regs than Tregs.1
Circulating levels of TNF, MCP1, IL-6, and IFN-g were reduced in
treated animals. Although few population changes were observed in
peripheral blood, there appears to be a systemic effect with siRNA
treatments. Analyzing these data, we can see the direct relation in
IL-6 and even a reduction of IFN-g with IRF5 silencing, thereby
corroborating the silencing of this pathway.6,42,43 Regarding IL-10,
the observed values showed a reduction in untreated groups. Higher
circulating levels should be expected in treated groups. However, in
the context of lupus, IL-10 is also related to the acceleration of renal
disease, as high serum levels of IL-10 are found in patients with
lupus.30,44 Thus, in this model, IL-10 expresses lupus disease activity,
and the reduction of systemic inflammation leads to this cytokine
reduction.
Information obtained from gene expression may evidence the
different pathways implicated in lupus, and in particular, nephritis.
Results showed that CYP, which is the gold standard treatment in
this model, but with excessive short- and long-term systemic toxic-
ities,45 modifies many genes related to a wide range of pathways.
On the contrary, both siRNAs modified fewer pathways, despite
showing similar clinical beneficial results. Therefore, IRF5 and BLYSS
silencing might be an effective and more specific treatment and by
regulating fewer pathways, perhaps fewer side effects may appear.
A subsequent set of experiments was performed including the combi-
nation of both siRNAs. Despite being a widely used and verified
model, differences in survival and disease outcome may be observed
between litters. So, the reproducibility of a biological effect confirms
its accuracy. Results in this second set of experiments showed a clearlyMolecular Therapy: Nucleic Acids Vol. 24 June 2021 815
Figure 7. Functional renal parameters for the second set of experiments throughout the study for all treatments
(A and B) Functional renal parameters for the second set of experiments including (A) proteinuria and (B) albuminuria by weight. Values are expressed in mg/kg for 24 h. (C)
Serum anti-dsDNA levels throughout the study for all treatments are expressed in kilo units/mL. Data are expressed as mean. a, p < 0.05 versus Veh; b, p < 0.05 versus SC.
Molecular Therapy: Nucleic Acidsmore severe disease in untreated animals. In this less friendly sce-
nario, both siIRF5 and siBLYSS monotherapy treatments reflected a
lower disease reduction compared with the previous experiment,
whereas CYP remains effective. Interestingly, the combination of
both siRNAs offered a significant reduction in the disease at similar
values to CYP, thus proving its additive potency.
Serum IRF5 and BLYSS levels revealed the efficacy in silencing those
genes. Although BLYSS expression is not significantly conditioned on
IRF5 expression, a connection between both targets must be consid-
ered due to the partial reduction in circulating BLYSS levels using
siIRF5 and its observed protective effect. siIRF5-treated group also
showed a significant reduction in IFN levels, thus proving its biolog-
ical effect.
Conclusions
Our data strongly support the potential therapeutic effects of both se-
lective IRF5 and BLYSS gene silencing as an effective new form of im-
mune deactivation in the inflamed kidney of animals with sponta-
neous autoimmune nephritis akin to human LN, particularly when
treatment is introduced during the early phases of the disease. It re-
mains to be seen whether disease remission could be achieved
through IRF5 and BLYSS gene interference initiated during the estab-
lished phase of the disease, since patients with LN often debut with816 Molecular Therapy: Nucleic Acids Vol. 24 June 2021established proteinuria and severe renal inflammation. Gene studies
and their relationship may be the subject of future studies.
MATERIALS AND METHODS
siRNA design and screening
siRNA duplexes targeting the partial mouse IRF5 mRNA sequence
(GenBank: NM_001252382; NCBI, Bethesda, MD, USA) and mouse
BLYSS mRNA sequence (GenBank: NM_033622.2; NCBI, Bethesda,
MD, USA) were designed. For the initial screening, fourteen
siRNAs were synthesized to test the inhibition potential in IRF5
expression (Table 1) and twelve siRNAs were synthesized to test
the inhibition potential in BLYSS expression (Table 2). A SC was
used as control for off-target effects. To assess the mouse IRF5
mRNA-silencing efficiency of siRNA molecules, we used in vitro cul-
ture of a RAW 264.7 cell line (macrophages). To assess the mouse
BLYSS mRNA-silencing efficiency, we used in vitro culture of an
MPC-11 cell line (B lymphocytes).
In vitro transfection of siRNAs (10 and 25 nM) was performed using
MIR6000 vector (TransIT-X2 Dynamic Delivery System, MirusBio,
Madison, WI, USA) following the manufacturer’s instructions.
Briefly, after achieving an 80% cell confluence, siRNA complexes
were previously prepared, with sufficient time for complexes to
form, and transfected into cell culture. After 24 h of incubation, cells
Table 4. Number of animals in the second set of experiments with levels
above 3 mg/dL concentration of proteinuria and the percentage they
represent in each group
Group Initial n Proteinuria outcome n Proteinuria outcome (%)
Vehicle 8 6 75
SC 7 4 57.1
IRF5 8 6 75
BLYSS 8 5 62.5
DUAL 10 2 20
CYP 8 1 12.5
www.moleculartherapy.orgwere harvested to perform the knockdown assay of target gene
expression.
siRNA properties
The siRNA BLYSS sequence used in this study consists of a 21-nucle-
otide sense and antisense strand. IRF5 and SC sequences used in this
study consist of a 21-nucleotide sense strand and 23-nucleotide anti-
sense strand, resulting in a two-nucleotide overhang at the 30 end of
the antisense strand. The siRNAmolecules were chemically stabilized
with partial phosphorothioate backbone and 20-O-methyl sugar
modification on the sense and antisense strands. The oligonucleotide
sequences were as follows: IRF5 sense strand, 50-CGA GAG AAG
CUC AUU ACU*Chol-30 and antisense strand, 50-AGU AAU GAG
CUU CUC UCZ*Z*G-30; BLYSS sense strand, 50-GAA AGG AGA
UAU GAA AdTdT*-Chol-30 and antisense strand, 50-UUU CAU
AUC UUC UCC UUU X*W*dT-30; and scrambled (SCR) sense
strand, 50-GUU GCAUUU CGU CUGGUAGGA*Chol-30 and anti-
sense strand, 50-UCCUACCAGACGAAAUGCAAX *Y*G-30, with
Z as 20-OMe-G, X as 20-OMe-C, Y as 20-OMe-U, dT as thymidine, the
asterisk (*) as phosphorothioate, and Chol as cholesterol modifica-
tion. Additionally, a conjugation of a cholesterol molecule to the 30
end of the sense strand of the siRNA molecule by means of a pyrro-
lidine linker was done. Scrambled siRNA was used as control. To
generate siRNAs from RNA single strands, equimolar amounts of
complementary sense and antisense strands were mixed and 100%
annealed. Anti-IRF5, anti-BLYSS, and scrambled siRNAs were ali-
quoted to avoid freeze-thaw cycles and stored at 20C.
Mice, study design, and follow-up
First set of experiments with siRNA transfection individually to
assess the effectiveness of siRNA in LNmodel and the potential
mechanisms implicated
Five-month-old NZB/WF1 mice (The Jackson Laboratory, Charles
River, Barcelona, Spain) were randomly assigned into five groups.
In this genetically modified mouse model, the renal disease began
early in the animal life, and there was a burst of clinical symptoms
later within 20–28 weeks. Next, we decided to begin treatments at
week 24 as follows: CYP, intraperitoneal cyclophosphamide (n = 8);
IRF5, intraperitoneal IRF5-siRNA (n = 8); BLYSS, intraperitoneal
BLYSS-siRNA (n = 8); SC (n = 7) intraperitoneal scrambled siRNA;
and Veh, intraperitoneal PBS as non-treated group (n = 8).Second set of experiments to retest effectiveness of siRNA
individually in LN model and to assess the superiority of
combined siRNA transfection
Five-month-old NZB/WF1 were randomly assigned into six groups.
At six months of age, treatments were initiated as follows: CYP, intra-
peritoneal CYP (n = 8); IRF5, intraperitoneal IRF5-siRNA (n = 8);
BLYSS, intraperitoneal BLYSS-siRNA (n = 8); DUAL, intraperitoneal
BLYSS-siRNA+IRF5-siRNA (n = 10); SC, intraperitoneal scrambled
siRNA (n = 7); and Veh, intraperitoneal PBS as non-treated group
(n = 8).
All siRNA molecules were administered 50 mg twice weekly following
our experience with other siRNAs as described previously.1,46 A vol-
ume of 200 mL of PBS was administered twice weekly. CYP was
administered in 50 mg/kg doses every 10 days. Mice were treated
for 12 weeks. Body weight was determined weekly from the beginning
to the end of follow-up. Mice were placed in metabolic cages to collect
24 h urine specimens before the onset of treatment and then monthly
thereafter. Blood was obtained from the tail vein at monthly intervals.
Kidneys were processed for histological and biochemical studies at
the end of the study or at death.
The experiments were carried out in accordance with current Euro-
pean Union (EU) legislation on animal experimentation and were
approved by CEEA (Animal Experimentation Ethics Committee),
the Institutional Ethics University of Barcelona (UB) Committee
for Animal Research, and the Animal Experimentation Commission
of the Generalitat de Catalunya (Catalonian Government). Mice were
housed in a room at constant temperature with a 12-h dark/12-h light
cycle, had free access to tap water, and were fed a standard laboratory
diet.
Renal function: Urinary total proteins, albumin, and creatinine
Twenty-four hour urinary protein was determined by pyrogallol red
reaction, and 24 h urinary creatinine measurement was performed
following Jaffe’s reaction (Autoanalyzer AU400, Olympus, Hamburg,
Germany) in the Veterinary Clinical Biochemistry Laboratory of Uni-
versitat Autonoma de Barcelona. Twenty-four hour urinary albumin
was determined using a commercially available ELISA kit (Active
Motif, Carlsbad, CA, USA) in accordance with the manufacturer’s in-
structions. The intensity of the fluorescent signal is directly propor-
tional to the albumin concentration in the sample.
Serum ELISA for cytokine and immunoglobulin analysis
Serum IL-12, TNF-a, IFN-g, and MCP1 cytokines were measured by
using a FACSCanto II cytometer with a cytometric bead array kit
(CBA mouse inflammation kit) in accordance with manufacturer’s
instructions. Data were acquired and analyzed using BD FCAP soft-
ware and CBA software (BD Biosciences, San Jose, CA, USA).
Analysis of phenotypic peripheral blood, spleen, and renal cell
populations with flow cytometry
Spleen and blood samples were processed in order to analyze the
different composition of immune cells. Peripheral blood was collectedMolecular Therapy: Nucleic Acids Vol. 24 June 2021 817
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Figure 9. Effect of different treatments in the mouse kidneys from the
second set of experiments
Representative histological images of hematoxylin and eosin staining and CD3+,
CD45RA+, and F4/80+ infiltrate using immunohistochemistry.
www.moleculartherapy.orgin heparin for flow cytometry protocol. Spleens were collected in PBS
for the splenocytes isolation by FicollH (GE Healthcare, Uppsala,
Sweden) density gradient and cryopreservation at 80C. For quan-
tifying the percentage of different populations, cells were thawed,
washed, and recovered by standard methods.
A volume of 100 mL of peripheral blood or 2  105 splenocytes were
added in every cytometry tube for flow cytometry protocol. Cytome-
try tubes were incubated in the dark (25 min at room temperature)
with antibodies. Study of populations was performed by using a BD
FACSCanto II cytometer and analyzed by BD FACSDiva software
(BD Biosciences, San Jose, CA, USA).
To characterize the different cell populations, anti-CD45R (clone
RA36B2), anti-CD23 (clone B3B4), anti-IgD (clone 11-26c.2a),
anti-CD19 (clone 1D3), anti-CD5 (clone 53-7.3), anti-CD1d (clone
1B1), anti-CD3 (clone 145-2c11), anti-CD4 (clone RM4-5), anti-
CD8a (clone 53-6.7), anti-PD-1 (clone 29F.1A12), anti-CD3e (cloneFigure 8. Renal histopathology parameters for the first set of experiments
(A) Semiquantitative inflammatory score values for hematoxylin and eosin stain. (B) Dot pl
for renal immunofluorescence CD3+ infiltrate and semiquantitative score for F4/80+ infil
mean ± SEM with individual dot plot representation. a, p < 0.05 versus Veh; b, p < 0.0145-2c11), anti-CD25 (clone PC61), anti-Fox P3 (clone FJK-16 s),
anti-IL-17a (clone TC11-18H10), anti-RORg (clone Q31-378),
anti-CD11c (clone HL3), anti-PDL-1 (clone MIH5), anti-PDL-2
(clone TY25), anti-F4/80 (clone 6F12), anti-CD11b (clone M1/70),
anti-CD86 (clone GL1), anti-CD206 (clone MR6F3), anti-CD115
(clone AFS98), and anti-Ly6C (clone 1G7.G10) were used. All anti-
bodies were provided by BD Biosciences (San Jose, CA, USA) and
MiltenyBiotec (Bergisch Gladbach, Germany), conveniently titrated,
mixed together, and formulated for optimal staining performance.
Renal lupus histopathology
For histological analysis, 1- to 2-mm-thick coronal slices of kidney
were fixed in 4% formaldehyde and embedded in paraffin. For light
microscopy, 3- to 4-mm-thick tissue sections were stained with hema-
toxylin and eosin and periodic acid-Schiff. To determine the extent of
renal damage, two pathologists blinded of information analyzed all
kidney biopsies. Characteristic glomerular active lesions of LN were
evaluated: mesangial expansion, endocapillary proliferation, glomer-
ular deposits, extracapillary proliferation, and interstitial infiltrates as
well as tubulo-interstitial chronic lesions, tubular atrophy, and inter-
stitial fibrosis. Lesions were graded semiquantitatively using a scoring
system from 0 to 3 (0 = no changes, 1 = mild, 2 = moderate, 3 = se-
vere). Finally, a total histological score was derived from the sum of all
the described items.
Paraffin tissue sections were stained for CD3 (Abcam, Cambridge,
UK) CD45RA (Abcam, Cambridge, UK), and F4/80 (LabClinics, Bar-
celona, Spain). Sections were de-paraffined and hydrated. The sec-
tions were blocked and immunoperoxidase labeled using a Vectastain
ABC kit and the avidin biotin blocking kit (Vector Laboratories, Bur-
lingame, CA, USA) in accordance with the manufacturer’s protocol.
Peroxidase-conjugated antibody staining was followed by diamino-
benzidine substrate development (Sigma-Aldrich, Madrid, Spain).
To quantify CD45RA (tubule and glomeruli) and F4/80 expression,
a semiquantitative intensity score from 0 to 3 was used. For quanti-
fying CD3 expression, at least 15 high-power fields were counted,
and the mean value was expressed.
Renal immunofluorescence studies
Slices of kidneys were fixed in 4% paraformaldehyde, embedded in
Tissue Tec optimal cutting temperature compound (Sakura, Alphen
aan den Rijn, the Netherlands), and stored at –80C. Fluorescent
staining of 5 mm cryostat sections was used for confocal microscopy
to quantify glomerular IgG and C3 deposition. Sections were directly
stained with a fluorescein isothiocyanate (FITC)-conjugated goat
anti-mouse IgG (Sigma-Aldrich, Madrid, Spain), and FITC-conju-
gated C3 (Nordic Immunology, Tilburg, the Netherlands). For anal-
ysis of C3 and IgG deposition, at least 10 glomeruli were visualized
and photographed with an immunofluorescence confocal microscopeot representation of total inflammatory score for each animal. (C) Cells per HPF values
trate and CD45RA+ tubular and glomerular infiltrate staining. Data are expressed as
5 versus SC.
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many). Fluorescence was quantified and normalized with Simulator
confocal software (Leica Microsystems) and is expressed as mean
fluorescence intensity.
RNA extraction, RT, and gene expression analysis: Quantitative
real-time PCR
For the screening of IRF5 and BLYSS siRNAs in cell culture, mRNA
expression of target genes was quantified by TaqMan real-time PCR
(ABI Prism 7700 Sequence Detection System, Applied Biosystems,
Madrid, Spain) using the comparative cycle threshold method
(Applied Biosystems, Madrid, Spain).
For molecular studies, the kidney was immediately snap-frozen in
liquid nitrogen and stored at80C. RNA was extracted from kidney
with PureLink RNAMini Kit (Invitrogen, Barcelona, Spain) in accor-
dance with the manufacturer’s instructions. RNA purity was analyzed
on a spectrophotometer (ND-1000V3.3, NanoDropWilmington, DE,
USA). All samples had an A260/280 ratio >1.8. RNA was stored at
80C. A total of 500 ng of RNAwas used to do the reverse transcrip-
tion using a High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Warrington, UK) following the manufacturer’s
instructions.
Kidney tissue expression of immune-inflammatory mediators was
quantified by TaqMan Low Density Array microfluidic cards
(Applied Biosystems, Warrington, UK) using the comparative cycle
threshold method. Controls, which were composed of distilled water,
were negative for target and reference genes.
Pathway analysis of single gene sets was set up using online https://
pathwax.sbc.su.se/ web server,47 which applies the BinoX algorithm
to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways
and FunCoup networks.
Statistical analysis
One-way analysis of variance (ANOVA) with post hoc tests was per-
formed to compare proteinuria, albuminuria, and anti-dsDNA anti-
bodies throughout the follow-up and gene expression and circulating
cytokines at sacrifice. To compare histological data, the non-para-
metric Kruskal-Wallis test was used. A p value <0.05 was considered
significant. Data are expressed as mean ± SEM.
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